Cologuard gets FDA approval for use in younger patients indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved the Exact Sciences Corp. noninvasive colorectal cancer screening test, Cologuard, for eligible average-risk individuals ages 45 and older, expanding on its previous indication for ages 50 and older.

Backed by science and clinical research in collaboration with Mayo Clinic, Cologuard is a stool DNA-based colorectal cancer screening test for average-risk individuals. Cologuard uses a biomarker panel that analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin).

Last year, the American Cancer Society updated its colorectal cancer screening guidelines to include people between the ages of 45 to 49. The prior ACS recommendation called for screening to begin at age 50 (The Cancer Letter, June 1, 2018).

The label expansion, or broadening of the population for whom Cologuard is FDA-approved, extends screening to approximately 19 million average-risk people in the U.S. ages 45-49.

“About three million people have been screened for colorectal cancer with Cologuard, with nearly half of those surveyed saying they were previously unscreened. With the FDA now approving the use of Cologuard for this vulnerable 45-49 age group, we are giving health care providers a sensitive, noninvasive option that has the potential to help combat the rise of colorectal cancer rates among this younger group of people,” Exact Sciences Chair and CEO Kevin Conroy said in a statement.

Exact Sciences has designed a nationwide user-navigation system that provides 24/7 phone and online support to help people through the process of collecting and returning their samples.

Table of Contents

YOU MAY BE INTERESTED IN

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
For patients with an HPV-related form of throat cancer, treatment is often highly effective, with cure rates as high as 90%, depending on the disease stage. Now, researchers are investigating whether some patients can safely avoid additional treatment while maintaining excellent cancer outcomes.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login